본문 바로가기
business
HOME
Business
免疫細胞治療剤
Pipeline

Pipeline

Autologous Immunotherapy

SNK01-US01 Clinical study in the U.S.

  • Target disease : Combination Therapy of Refractory Cancer + Pembrolizumab or Avelumab
  • Trial No. : NCT03941262 Learn more
  • Discovery
  • Preclinical
  • Phase I
  • Phase II

SNK01-N12a Clinical study in Korea

  • Target disease : Combination therapy of non-small cell lung cancer + pembrolizumab
  • Trial No. : KCT0003463 Learn more
  • Discovery
  • Preclinical
  • Phase I
  • Phase II

SNK01-TRN12a Clinical study in Korea

  • Target disease : Combination therapy of non-small cell lung cancer + Chemotherapy or Cetuximab
  • Trial No. : NCT04872634 Learn more
  • Discovery
  • Preclinical
  • Phase I
  • Phase II

SNK01-AFM24 Clinical study in the U.S.

  • Target disease : Combination Therapy of EGFR-positive Cancer + AFM24
  • Trial No. : NCT05099549 Learn more
  • Discovery
  • Preclinical
  • Phase I
  • Phase II

SNK01-MX03 Clinical study in Mexico

  • Target disease : Psoriasis (autoimmune disease)
  • Trial No. : NCT03894579 Learn more
  • Discovery
  • Preclinical
  • Phase I
  • Phase II

SNK01-MX04 Clinical study in Mexico

  • Target disease : Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD)
  • Discovery
  • Preclinical
  • Phase I
  • Phase II

Allogenic Immunotherapy

  • Discovery
  • Preclinical
  • Phase I
  • Phase II

CAR-NK

  • Discovery
  • Preclinical
  • Phase I
  • Phase II

Move to Top